HIF1A and breast cancer: miR-6883 was transfected into cells under normoxia or hypoxia and western blot analysis revealed that miR-6883 downregulates CDK4/6 and HIF1α in CRC and BC cells, pointing to miR-6883 as a promising therapeutic to target hypoxic tumors or HIF1α-deregulated cancer cells.